LICENSE ASSIGNMENT AGREEMENT

THIS AGREEMENT is dated February 18, 2019 (the "**Effective Date**")

BETWEEN:

BULLRUN CAPITAL INC., a corporation existing under the laws of the Province of British Columbia

(the "**Assignor**")

AND:

FIRST RESPONDER TECHNOLOGIES INC., a corporation existing under the laws of the Province of British Columbia

(the "**Assignee**")

WHEREAS:

(A) The Assignor and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute ("**NCI**") entered into a patent license agreement dated February 14, 2019 (the "**License Agreement**", attached hereto as Schedule "A"), pursuant to which NCI granted the Assignor a nonexclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use (collectively, the "**NCI License**");

(B) The Assignor wishes to assign all of its rights, titles and interests in and to the NCI License to the Assignee; and

(C) The parties now wish to document their assignment agreement in writing.

NOW THEREFORE, in consideration of the mutual promises, covenants, warranties, and other good and valuable consideration set forth herein, and in accordance with applicable law, the parties hereby agree as follows:

PART 1
DEFINITIONS

1.1 **Certain Defined Terms**. Capitalized terms used but not defined herein shall have the meanings assigned to them in the License Agreement.

1.2 **Currency**. Unless otherwise indicated, all dollar amounts referred to in this Agreement are in Canadian funds.

1.3 **Number and Gender**. Where the context requires, words imparting the singular shall include the plural and vice versa, and words imparting gender shall include all genders.

1.4 **Headings**. Headings contained in this Agreement are included solely for convenience, are not intended to be full or accurate descriptions of the content thereof and shall not be considered part of this Agreement or affect the construction or interpretation of any provision hereof.

PART 2
ASSIGNMENT

2.1 **Assignment**. Subject to the terms and conditions in this Agreement and in consideration of the payment stipulated in Section 2.3 hereunder, the Assignor hereby assigns to the Assignee, as of the Effective Date, all of the Assignor's right, title and interest in or to the NCI License.

2.2 **Acceptance of Assignment**. Subject to the terms and conditions in this Agreement and in consideration of the payment stipulated in Section 2.3 hereunder, the Assignee hereby accepts the assignment herein and agrees to assume the obligations of the Assignor under the NCI License from and after the Effective Date.

2.3 **Payment**. In consideration of the assignment of the NCI License pursuant to this Agreement, and of the promises and covenants contained herein, the Assignee shall issue to Assignor 10,000,000 common shares in the capital of the Assignee (each a "**Common Share**") on the Effective Date, as more specifically set forth in Schedule "B" attached hereto.

PART 3
WARRANTY

3.1 The Assignor does not bind itself and makes no representation or warranty of any kind whatsoever with respect to the NCI License, without limiting the generality of the foregoing, the Assignor makes no representation or warranty of any kind whatsoever with respect to the usefulness, quality or marketability of the NCI License, or the effects which may result from their use or that the development of applications relating to the NCI License is complete. The Assignor shall not be liable for the warranties, representations, undertakings or any other obligations given or assumed by the Assignee toward any party whomsoever with respect to the manufacturing, promotion, distribution, use or sale of any product and services or any other activity relating thereto or to the NCI License.

PART 4
REPRESENTATIONS AND WARRANTIES

4.1 **Assignor's Representations and Warranties**. The Assignor hereby represents and warrants to the Assignee:

(a) that it has the sole legal right and authority to execute this Agreement, and to validly assign to the Assignee all of the right, title and interest in and to the NCI License;

(b) that it has not executed any other agreement that would conflict with the terms of this Agreement, nor shall it execute any such agreement in the future;

(c) that it will, at the request of the Assignee, assist the Assignee in effecting the formal transfer and recording of the assignment of the NCI License, as required;

(d) that it will execute any additional documents, including, without limitation, any forms of transfer, and do such acts or other things as may be required to effect or confirm the transfer and assignment of the NCI License to the Assignee; and

(e) that there are no existing proceedings with regards to third party infringement related to the NCI License.

4.2 **Assignee's Representations and Warranties**. The Assignee hereby represent and warrant to Assignor that:

(a) the Assignee has the full legal right and authority to execute this Agreement, and to accept the assignment of the right, title and interest in and to the NCI License;

(b) the Assignee has not executed any other agreement that would conflict with the terms of this Agreement, nor shall the Assignee execute any such agreement in the future; and

(C) it undertakes not to do, or cause, help or assist anybody to do, whether directly or indirectly, anything which may, in any manner whatsoever, imperil or infringe the validity of the NCI License.

PART 5
GENERAL TERMS

5.1 **Further Actions**. The Assignor hereby agrees to execute any further agreements or documents and to take any further actions necessary to aid the Assignee in perfecting its interest in the NCI License and in enforcing any and all protections or privileges deriving from the NCI License.

5.2 **Severability**. If any part or parts of this Agreement shall be held unenforceable for any reason, the remainder of this Agreement shall continue in full force and effect. If any provision of this Agreement is deemed invalid or unenforceable by any court of competent jurisdiction, and if limiting such provision would make the provision valid, then such provision shall be deemed to be construed as so limited and the parties shall seek to negotiate a replacement provision in good faith, such replacement provision having insofar as possible, the same economic and legal effect as the severed provision.

5.3 **Notice**. Any notice required or otherwise given pursuant to this Agreement shall be in writing and mailed certified return receipt requested, postage prepaid, or delivered by overnight delivery service, addressed as follows:

If to Assignor:

Bullrun Capital Inc.
4873 Delta Street
Delta, British Columbia V4K 2T9
Attention: Kal Malhi
Email: kal@bullruncapital.ca

If to Assignee:

First Responder Technologies Inc.
c/o McMillan LLP
1500 – 1055 West Georgia Street

Vancouver, British Columbia V6E 4N7
Attention: Desmond Balakrishnan
Email: desmond.balakrishnan@mcmillan.ca

5.4 **Amendments**. This Agreement shall not be amended, altered or modified except by an instrument in writing expressly referring to this Agreement and signed by all of the parties hereto. The foregoing shall also apply to any modification of or deviation from this written form requirement.

5.5 **Governing Law**. This Agreement shall be interpreted in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein, and each of the parties irrevocably attorns to the exclusive jurisdiction of the courts of British Columbia.

5.6 **Entire Agreement**. This Agreement constitutes the entire agreement between the Assignor and the Assignee, and supersedes any prior understanding or representation of any kind preceding the date of this Agreement. There are no other promises, conditions, understandings or other agreements, whether oral or written, relating to the subject matter of this Agreement.

5.7 **Counterparts**. This Agreement may be executed in two or more counterparts, and delivered by electronic transmission, each of which shall be deemed to be an original and all of which together shall constitute one and the same.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed the day and year first above written.

BULLRUN CAPITAL INC.

Per: _____
Name: Kal Malik
Title: Chairman

FIRST RESPONDER TECHNOLOGIES INC.

Per: _____
Name: Christopher J. Moreau
Title: President

SCHEDULE "A"

THE LICENSE AGREEMENT

PUBLIC HEALTH SERVICE

PATENT LICENSE-NON-EXCLUSIVE

This **Agreement** is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public Health Service ("**PHS**") Technology Transfer Policy Board for use by components of the National Institutes of Health ("**NIH**"), the Centers for Disease Control and Prevention ("**CDC**"), and the Food and Drug Administration ("**FDA**"), which are agencies of the **PHS** within the Department of Health and Human Services ("**HHS**").

This Cover Page identifies the Parties to this **Agreement**:

The U.S. Department of Health and Human Services, as represented by

The National Cancer Institute

an Institute or Center (hereinafter referred to as the "**IC**") of the

FDANIH

and

Bullrun Capital, Inc.,

hereinafter referred to as the "**Licensee**",

having offices at Suite 915 – 700 West Pender Street, Vancouver, BC, Canada V6C 1G8,

created and operating under the laws of Canada.

Tax ID No.: 842028912RT0001

For the **IC** internal use only:

License Number: L-123-2019-0

License Application Number: A-493-2018

Serial Number(s) of Licensed Patent(s) or Patent Application(s):

U.S. Patent Application Serial No 15/010,830, filed January 29, 2016, **HHS** Reference Number E-048-2010-0-US-05, titled "Agonist/antagonist compositions and methods of use";

U.S. Patent 9,277,748 (Application No. 13/634,447) filed March 11, 2011, issued March 8, 2016, titled "Agonist/antagonist compositions and methods of use", **HHS** Ref. No.: E-048-2010-0-US-04;

Canada Patent Application Serial No. 2,792,878, filed March 11, 2011, **HHS** Reference Number E-048-2010-0-CA-03 titled "Agonist/antagonist compositions and methods of use";

PCT Patent Application Serial No. PCT/US2011/028132, filed March 11, 2011, now abandoned, **HHS** Reference Number E-048-2010-0-PCT-02 titled "Agonist/antagonist compositions and methods of use"; and

U.S. Provisional Patent Application No. 61/340,063, filed March 12, 2018, now abandoned, titled "Agonist/Antagonist Compositions and Methods of Use", **HHS** Ref. No.: E-048-2010-0-US-01.

Licensee: Bullrun Capital, Inc.

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A

Additional Remarks: N/A

Public Benefit(s): This technology may fill a public health need by improving safety over currently available pepper sprays.

This Patent License Agreement, hereinafter referred to as the "**Agreement**", consists of this Cover Page, an attached **Agreement**, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

The **IC** and the **Licensee** agree as follows:

1. BACKGROUND

1.1 In the course of conducting biomedical and behavioral research, the **IC** investigators made inventions that may have commercial applicability.

1.2 By assignment of rights from the **IC** employees and other inventors, **HHS**, on behalf of the **Government**, owns intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assigned inventions. **HHS** also owns any tangible embodiments of these inventions actually reduced to practice by the **IC**.

1.3 The Secretary of **HHS** has delegated to the **IC** the authority to enter into this **Agreement** for the licensing of rights to these inventions under 35 U.S.C. §§200-212, the Federal Technology Transfer Act of 1986, 15 U.S.C. §3710(a), and the regulations governing the licensing of Government-owned inventions, 37 C.F.R. Part 404.

1.4 The **IC** desires to transfer these inventions to the private sector through commercialization licenses to facilitate the commercial development of products and processes for public use and benefit.

1.5 The **Licensee** desires to acquire commercialization rights to certain of these inventions in order to develop processes, methods, or marketable products for public use and benefit.

2. DEFINITIONS

2.1 "**Affiliate(s)**" means a corporation or other business entity, which directly or indirectly is controlled by or controls, or is under common control with the **Licensee**. For this purpose, the term "control" shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity.

2.2 "**Benchmarks**" mean the performance milestones that are set forth in Appendix D.

2.3 "**Commercial Development Plan**" means the written commercialization plan attached as Appendix E.

2.4 "**First Commercial Sale**" means the initial transfer by or on behalf of the **Licensee** of **Licensed Products** or the initial practice of a **Licensed Process** by or on behalf of the **Licensee** in exchange for cash or some equivalent to which value can be assigned for the purpose of determining **Net Sales**.

2.5 "**FDA**" means the Food and Drug Administration.

2.6 **First Responder Inc.** means a corporation having an address of Suite 915 – 700 West Pender Street, Vancouver, BC, Canada V6C 1G8, a company of which **Licensee** is the initial founding shareholder having all of the issued and outstanding shares upon organization and the right to appoint the initial directors of same.

2.7 "**Government**" means the Government of the United States of America.

2.8 "**Licensed Fields of Use**" means the fields of use identified in Appendix B.

2.9 "**Licensed Patent Rights**" shall mean:

(a) Patent applications (including provisional patent applications and PCT patent applications) or patents listed in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents;

(b) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.9(a):

(i) continuations-in-part of 2.9(a);

(ii) all divisions and continuations of these continuations-in-part;

(iii) all patents issuing from these continuations-in-part, divisions, and continuations;

(iv) priority patent application(s) of 2.9(a); and

(v) any reissues, reexaminations, and extensions of all these patents;

(c) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.9(a): all counterpart foreign and U.S. patent applications and patents to 2.9(a) and 2.9(b), including those listed in Appendix A; and

(d) **Licensed Patent Rights** shall *not* include 2.9(b) or 2.9(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.9(a).

2.10 "**Licensed Processes**" means processes, which in the course of being practiced, would be within the scope of one or more claims of the **Licensed Patent Rights** that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

2.11 "**Licensed Products**" means tangible materials, which in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the **Licensed Patent Rights** that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

2.12 "**Licensed Territory**" means the geographical area identified in Appendix B.

2.13 "**Net Sales**" means the total gross receipts for sales of **Licensed Products** or practice of **Licensed Processes** by or on behalf of the **Licensee**, and from leasing, renting, or otherwise making **Licensed Products** available to others without sale or other dispositions, whether invoiced or not, less returns and allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted. No deductions shall be made for commissions paid to individuals, whether they are with independent sales agencies or regularly employed by the **Licensee**, and on its payroll, or for the cost of collections.

2.14 "**Practical Application**" means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or **Government** regulations available to the public on reasonable terms.

3. GRANT OF RIGHTS

3.1 The **IC** hereby grants and the **Licensee** accepts, subject to the terms and conditions of this **Agreement**, a nonexclusive license under the **Licensed Patent Rights** in the **Licensed Territory** to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any **Licensed Products** in the **Licensed Fields of Use** and to practice and have practiced any **Licensed Processes** in the **Licensed Fields of Use**.

3.2 This **Agreement** confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of the **IC** other than the **Licensed Patent Rights** regardless of whether these patents are dominant or subordinate to the **Licensed Patent Rights**.

4. SUBLICENSING

4.1 The **Licensee** has no right to sublicense

5. STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS

5.1 Prior to the **First Commercial Sale**, the **Licensee** agrees to provide the **IC** with reasonable quantities of **Licensed Products** or materials made through the **Licensed Processes** for **IC** research use.

5.2 The **Licensee** agrees that products used or sold in the United States embodying **Licensed Products** or produced through use of **Licensed Processes** shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the **IC**.

6. ROYALTIES AND REIMBURSEMENT

6.1 The **Licensee** agrees to pay the **IC** a noncreditable, nonrefundable license issue royalty as set forth in Appendix C.

6.2 The **Licensee** agrees to pay the **IC** a minimum annual royalty as set forth in Appendix C.

6.3 The **Licensee** agrees to pay the **IC** earned royalties as set forth in Appendix C.

6.4 The **Licensee** agrees to pay the **IC** benchmark royalties as set forth in Appendix C.

6.5 A patent or patent application licensed under this **Agreement** shall cease to fall within the **Licensed Patent Rights** for the purpose of computing earned royalty payments in any given country on the earliest of the dates that:

(a) the application has been abandoned and not continued;

(b) the patent expires or irrevocably lapses; or

(c) the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or administrative agency.

6.6 No multiple royalties shall be payable because any **Licensed Products** or **Licensed Processes** are covered by more than one of the **Licensed Patent Rights**.

6.7 On sales of **Licensed Products** by the **Licensee** made in other than an arms-length transaction, the value of the **Net Sales** attributed under this Article 6 to this transaction shall be that which would have been received in an arms-length transaction, based on sales of like quantity and quality products on or about the time of this transaction.

6.8 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the **Licensed Patent Rights** and paid by the **IC** prior to the effective date of this **Agreement**, the **Licensee** shall pay the **IC**, as an additional royalty, not to exceed seventy thousand Dollars ($70,000), within sixty (60) days of the **IC's** submission of a statement and request for payment to the **Licensee**, an amount equivalent to the unreimbursed patent expenses previously paid by the **IC**. With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the **Licensed Patent Rights** and paid by the **IC** on or after the effective date of this **Agreement**, the **IC**, at its sole option, may require the **Licensee**:

(a) to pay the **IC** on an annual basis, within sixty (60) days of the **IC's** submission of a statement and request for payment, a royalty amount equivalent to these unreimbursed expenses paid during the previous calendar year(s); said expenses being divided amongst all licensees to the **Licensed Patent Rights**, should any other such licenses be executed;

(b) to pay these unreimbursed expenses directly to the law firm employed by the **IC** to handle these functions. However, in this event, the **IC** and not the **Licensee** shall be the client of the law firm; or

(c) under exceptional circumstances, the **Licensee** may be given the right to assume responsibility for the preparation, filing, prosecution, or maintenance of any patent application or patent included with the **Licensed Patent Rights**. In that event, the **Licensee** shall directly pay the attorneys or agents engaged to prepare, file, prosecute, or maintain these patent applications or patents and shall provide the **IC** with copies of each invoice associated with these services as well as documentation that these invoices have been paid.

6.9 The **IC** agrees, upon written request, to provide the **Licensee** with summaries of patent prosecution invoices for which the **IC** has requested payment from the **Licensee** under Paragraphs 6.8 and 6.9. The **Licensee** agrees that all information provided by the **IC** related to patent prosecution costs shall be treated as confidential commercial information and shall not be released to a third party except as required by law or a court of competent jurisdiction.

6.10 The **Licensee** may elect to surrender its rights in any country of the **Licensed Territory** under any of the **Licensed Patent Rights** upon sixty (60) days written notice to the **IC** and owe no payment obligation under Paragraph 6.9 for patent-related expenses paid in that country after the effective date of the written notice.

7. PATENT FILING, PROSECUTION, AND MAINTENANCE

7.1 The **IC** agrees to take responsibility for the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the **Licensed Patent Rights**, but to consult with, the **Licensee** in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the **Licensed Patent Rights** and shall furnish copies of relevant patent related documents to the **Licensee**.

8. RECORD KEEPING

8.1 The **Licensee** agrees to keep accurate and correct records of **Licensed Products** made, used, sold, or imported and **Licensed Processes** practiced under this **Agreement** appropriate to determine the amount of royalties due the **IC**. These records shall be retained for at least five (5) years following a given reporting period and shall be available during normal business hours for inspection, at the expense of the **IC**, by an accountant or other designated auditor selected by the **IC** for the sole purpose of verifying reports and royalty payments hereunder. The accountant or auditor shall only disclose to the **IC** information relating to the accuracy of reports and royalty payments made under this **Agreement**. If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then the **Licensee** shall reimburse the **IC** for the cost of the inspection at the time the **Licensee** pays the unreported royalties, including any additional royalties as required by Paragraph 9.7. All royalty payments required under this Paragraph shall be due within sixty (60) days of the date the **IC** provides the **Licensee** notice of the payment due.

9. REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS

9.1 Prior to signing this **Agreement**, the **Licensee** has provided the **IC** with the **Commercial Development Plan** in Appendix E, under which the **Licensee** intends to bring the subject matter of the **Licensed Patent Rights** to the point of **Practical Application**. This **Commercial Development Plan** is hereby incorporated by reference into this **Agreement**. Based on this plan, performance **Benchmarks** are determined as specified in Appendix D.

9.2 The **Licensee** shall provide written annual reports on its product development progress or efforts to commercialize under the **Commercial Development Plan** for each of the **Licensed Fields of Use** within sixty (60) days after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and development, status of applications for regulatory approvals, manufacture, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. The **IC** also encourages these reports to include information on any of the **Licensee's** public service activities that relate to the **Licensed Patent Rights**. If reported progress differs from that projected in the **Commercial Development Plan** and **Benchmarks**, the **Licensee** shall explain the reasons for such differences. In any annual report, the **Licensee** may propose amendments to the **Commercial Development Plan**, acceptance of which by the **IC** may not be denied unreasonably. The **Licensee** agrees to provide any additional information reasonably required by the **IC** to evaluate the **Licensee's** performance under this **Agreement**. The **Licensee** may amend the **Benchmarks** at any time upon written approval by the **IC**. The **IC** shall not unreasonably withhold approval of any request of the **Licensee** to extend the time periods of this schedule if the request is supported by a reasonable showing by the **Licensee** of diligence in its performance under the **Commercial Development Plan** and toward bringing the **Licensed Products** to the point of **Practical Application**.

9.3 The **Licensee** shall report to the **IC** the dates for achieving **Benchmarks** specified in Appendix D and the **First Commercial Sale** in each country in the **Licensed Territory** within thirty (30) days of such occurrences.

9.4 The **Licensee** shall submit to the **IC**, within sixty (60) days after each calendar half-year ending June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the **Licensed Products** sold or **Licensed Processes** practiced by or on behalf of the **Licensee** in each country within the **Licensed Territory**, the **Net Sales**, and the amount of royalty accordingly due. With each royalty report, the **Licensee** shall submit payment of earned royalties due. If no earned royalties are due to the **IC** for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the **Licensee** and shall include a detailed listing of all deductions made under Paragraph 2.13 to determine **Net Sales** made under Article 6 to determine royalties due.

9.5 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in *The Wall Street Journal* on the day that the payment is due, and any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the **Licensee**. The royalty report required by Paragraph 9.4 shall be mailed to the **IC** at its address for **Agreement** Notices indicated on the Signature Page.

9.6 The **Licensee** shall be solely responsible for determining if any tax on royalty income is owed outside the United States and shall pay this tax and be responsible for all filings with appropriate agencies of foreign governments.

9.7 Additional royalties may be assessed by the **IC** on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the **IC** of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent the **IC** from exercising any other rights it may have as a consequence of the lateness of any payment.

9.8 All plans and reports required by this Article 9 and marked "confidential" by the **Licensee** shall, to the extent permitted by law, be treated by the **IC** as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the **IC** under the Freedom of Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d).

10. PERFORMANCE

10.1 The **Licensee** shall use its reasonable commercial efforts to bring the **Licensed Products** and **Licensed Processes** to **Practical Application**. "Reasonable commercial efforts" for the purposes of this provision shall include adherence to the **Commercial Development Plan** in Appendix E and performance of the **Benchmarks** in Appendix D.

10.2 Upon the **First Commercial Sale**, until the expiration or termination of this **Agreement**, the **Licensee** shall use its reasonable commercial efforts to make **Licensed Products** and **Licensed Processes** reasonably accessible to the United States public.

10.3 The **Licensee** agrees, after its **First Commercial Sale,** to make reasonable quantities of **Licensed Products** or materials produced through the use of **Licensed Processes** available to patient assistance programs.

10.4 The **Licensee** agrees, after its **First Commercial Sale** and as part of its marketing and product promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the **Licensed Products** or medical aspects of the prophylactic and therapeutic uses of the **Licensed Products**.

10.5 The **Licensee** agrees to supply, to the Mailing Address for **Agreement** Notices indicated on the Signature Page, the Office of Technology Transfer, the **NIH** with inert samples of the **Licensed Products** or **Licensed Processes** or their packaging for educational and display purposes only.

11. INFRINGEMENT AND PATENT ENFORCEMENT

11.1 The **IC** and the **Licensee** agree to notify each other promptly of each infringement or possible infringement of the **Licensed Patent Rights**, as well as, any facts which may affect the validity, scope, or enforceability of the **Licensed Patent Rights** of which either Party becomes aware.

11.2 In the event that a declaratory judgment action alleging invalidity of any of the **Licensed Patent Rights** shall be brought against the **IC**, the **IC** agrees to notify the **Licensee** that an action alleging invalidity has been brought. The **IC** does not represent that it shall commence legal action to defend against a declaratory action alleging invalidity. The **Licensee** shall take no action to compel the **Government** either to initiate or to join in any declaratory judgment action. Should the **Government** be made a party to any suit by motion or any other action of the **Licensee**, the **Licensee** shall reimburse the **Government** for any costs, expenses, or fees, which the **Government** incurs as a result of the motion or other action. Upon the **Licensee's** payment of all costs incurred by the **Government** as a result of the **Licensee's** joinder motion or other action, these actions by the **Licensee** shall not be considered a default in the performance of any material obligation under this **Agreement**.

12. NEGATION OF WARRANTIES AND INDEMNIFICATION

12.1 The **IC** offers no warranties other than those specified in Article 1.

12.2 The **IC** does not warrant the validity of the **Licensed Patent Rights** and makes no representations whatsoever with regard to the scope of the **Licensed Patent Rights**, or that the **Licensed Patent Rights** may be exploited without infringing other patents or other intellectual property rights of third parties.

12.3 THE **IC** MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE **LICENSED PATENT RIGHTS** OR TANGIBLE MATERIALS RELATED THERETO.

12.4 The **IC** does not represent that it shall commence legal actions against third parties infringing the **Licensed Patent Rights**.

12.5 The **Licensee** shall indemnify and hold the **IC**, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

(a) the use by or on behalf of the **Licensee**, its directors, employees, or third parties of any **Licensed Patent Rights**; or

(b) the design, manufacture, distribution, or use of any **Licensed Products**, **Licensed Processes** or materials by the **Licensee**, or other products or processes developed in connection with or arising out of the **Licensed Patent Rights**.

12.6 The **Licensee** agrees to maintain a liability insurance program consistent with sound business practice.

13. TERM, TERMINATION, AND MODIFICATION OF RIGHTS

13.1 This **Agreement** is effective when signed by all parties, unless the provisions of Paragraph 14.15 are not fulfilled, and shall extend to the expiration of the last to expire of the **Licensed Patent Rights** unless sooner terminated as provided in this Article 13.

13.2 In the event that the **Licensee** is in default in the performance of any material obligations under this **Agreement**, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the **IC** may terminate this **Agreement** by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act.

13.3 In the event that the **Licensee** becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, determines to file a petition in bankruptcy, or receives notice of a third party's intention to file an involuntary petition in bankruptcy, the **Licensee** shall immediately notify the **IC** in writing.

13.4 The **Licensee** shall have a unilateral right to terminate this **Agreement** in any country or territory by giving the **IC** sixty (60) days written notice to that effect.

13.5 The **IC** shall specifically have the right to terminate or modify, at its option, this **Agreement**, if the **IC** determines that the **Licensee**:

(a) is not executing the **Commercial Development Plan** submitted with its request for a license and the **Licensee** cannot otherwise demonstrate to the **IC's** satisfaction that the **Licensee** has taken, or can be expected to take within a reasonable time, effective steps to achieve **Practical Application** of the **Licensed Products** or **Licensed Processes**;

(b) has not achieved the **Benchmarks** as may be modified under Paragraph 9.2;

(c) has willfully made a false statement of, or willfully omitted, a material fact in the license application or in any report required by this **Agreement**;

(d) has committed a material breach of a covenant or agreement contained in this **Agreement**;

(e) is not keeping **Licensed Products** or **Licensed Processes** reasonably available to the public after commercial use commences;

(f) cannot reasonably satisfy unmet health and safety needs; or

(g) cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2, unless waived.

13.6 In making the determination referenced in Paragraph 13.5, the **IC** shall take into account the normal course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the **Licensee** under Paragraph 9.2. Prior to invoking termination or modification of this **Agreement** under Paragraph 13.5, the **IC** shall give written notice to the **Licensee** providing the **Licensee** specific notice of, and a ninety (90) day opportunity to respond to, the **IC's** concerns as to the items referenced in 13.5(a)-13.5(g). If the **Licensee** fails to alleviate the **IC's** concerns as to the items referenced in 13.5(a)-13.5(g) or fails to initiate corrective action to the **IC's** satisfaction, the **IC** may terminate this **Agreement**.

13.7 The **IC** reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this **Agreement** if it is determined that the action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the **Licensee**.

13.8 Within thirty (30) days of receipt of written notice of the **IC's** unilateral decision to modify or terminate this **Agreement**, the **Licensee** may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated the **IC** official. The decision of the designated **IC** official shall be the final agency decision. The **Licensee** may thereafter exercise any and all administrative or judicial remedies that may be available.

13.9 Within ninety (90) days of expiration or termination of this **Agreement** under this Article 13, a final report shall be submitted by the **Licensee**. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expense, due to the **IC** shall become immediately due and payable upon termination or expiration. Unless otherwise specifically provided for under this **Agreement**, upon termination or expiration of this **Agreement**, the **Licensee** shall return all **Licensed Products** or other materials included within the **Licensed Patent Rights** to the **IC** or provide the **IC** with written certification of the destruction thereof. The **Licensee** may not be granted additional **IC** licenses if the final reporting requirement is not fulfilled.

14. GENERAL PROVISIONS

14.1 Neither party may waive or release any of its rights or interests in this **Agreement** except in writing. The failure of the **Government** to assert a right hereunder or to insist upon compliance with any term or condition of this **Agreement** shall not constitute a waiver of that right by the **Government** or excuse a similar subsequent failure to perform any of these terms or conditions by the **Licensee**.

14.2 This **Agreement** constitutes the entire agreement between the Parties relating to the subject matter of the **Licensed Patent Rights**, **Licensed Products** and **Licensed Processes**, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this **Agreement**.

14.3 The provisions of this **Agreement** are severable, and in the event that any provision of this **Agreement** shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this **Agreement**.

14.4 If either party desires a modification to this **Agreement**, the parties shall, upon reasonable notice of the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this **Agreement** or their designees.

14.5 The construction, validity, performance, and effect of this **Agreement** shall be governed by Federal law as applied by the Federal courts in the District of Columbia.

14.6 All **Agreement** notices required or permitted by this **Agreement** shall be given by prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the Signature Page, or to any other address as may be designated in writing by such other party. **Agreement** notices shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.

14.7 This **Agreement** shall not be assigned or otherwise transferred (including any transfer by legal process or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to the **Licensee's Affiliate(s)** or to **First Responder, Inc.** without the prior written consent of the **IC**. The parties agree that the identity of the parties is material to the formation of this **Agreement** and that the obligations under this **Agreement** are nondelegable. In the event that the **IC** approves a proposed assignment, the **Licensee** shall pay the **IC**, as an additional royalty, one percent (1%) of the fair market value of any consideration received for any assignment of this **Agreement** within sixty (60) days of the assignment

14.8 The **Licensee** agrees in its use of any **IC**-supplied materials to comply with all applicable statutes, regulations, and guidelines, including **NIH** and **HHS** regulations and guidelines. The **Licensee** agrees not to use the materials for research involving human subjects or clinical trials in the United States without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The **Licensee** agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the **IC**, in writing, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the **IC** of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of the research or trials.

14.9 The **Licensee** acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological materials, and other commodities. The transfer of these items may require a license from the appropriate agency of the **Government** or written assurances by the **Licensee** that it shall not export these items to certain foreign countries without prior approval of the agency. The **IC** neither represents that a license is or is not required or that, if required, it shall be issued.

14.10 The **Licensee** agrees to mark the **Licensed Products** or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate "Patent Pending" status. All **Licensed Products** manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve the **IC** patent rights in those countries.

14.11 By entering into this **Agreement**, the **IC** does not directly or indirectly endorse any product or service provided, or to be provided, by the **Licensee** whether directly or indirectly related to this **Agreement**. The **Licensee** shall not state or imply that this **Agreement** is an endorsement by the **Government**, the **IC**, any other **Government** organizational unit, or any **Government** employee. Additionally, the **Licensee** shall not use the names of the **IC**, the **FDA**, **HHS**, or the **Government** or their employees in any advertising, promotional, or sales literature without the prior written approval of the **IC**.

14.12 The Parties agree to attempt to settle amicably any controversy or claim arising under this **Agreement** or a breach of this **Agreement**, except for appeals of modifications or termination decisions provided for in Article 13. The **Licensee** agrees first to appeal any unsettled claims or controversies to the designated **IC** official, or designee, whose decision shall be considered the final agency decision. Thereafter, the **Licensee** may exercise any administrative or judicial remedies that may be available.

14.13 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the source of the grant.

14.14 Paragraphs 8.1, 9.6-9.8, 12.1-12.5, 13.8, 13.9, 14.12 and 14.14 of this **Agreement** shall survive termination of this **Agreement**.

14.15 The terms and conditions of this **Agreement** shall, at the **IC's** sole option, be considered by the **IC** to be withdrawn from the **Licensee's** consideration and the terms and conditions of this **Agreement**, and the **Agreement** itself to be null and void, unless this **Agreement** is executed by the **Licensee** and a fully executed original is received by the **IC** within sixty (60) days from the date of the **IC** signature found at the Signature Page.

SIGNATURES BEGIN ON NEXT PAGE

NIH PATENT LICENSE AGREEMENT – *NONEXCLUSIVE*

SIGNATURE PAGE

For the **IC**: Richard U. Rodriguez -S Digitally signed by Richard U. Rodriguez -S Date: 2019.02.14 10:02:13 -05'00'

2-14-19
Date

Richard U. Rodriguez, MBA
Associate Director, TTC
National Cancer Institute
National Institutes of Health

Mailing Address or E-mail Address for **Agreement** notices and reports:

License Compliance and Administration
Monitoring & Enforcement
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, Maryland 20852-3804 U.S.A.

E-mail: LicenseNotices_Reports@mail.nih.gov

For the **Licensee** (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the **Licensee** made or referred to in this document are truthful and accurate.):

by:

Signature of Authorized Official

Feb 14/19.
Date

Kal Malhi
Printed Name

Chairman
Title

I. Official and Mailing Address for **Agreement** notices:

Kal Malhi
Name

CEO
Title

Mailing Address
915-700 W Pender Street
Vancouver, BC, CANADA V6C 1H2

Bullrun Capital Inc.

Suite 915 – 700 West Pender Street

Vancouver, BC, Canada

Email Address: kal@bullruncapital.ca

Phone: 604-805-4602

Fax:

II. Official and Mailing Address for Financial notices (the **Licensee's** contact person for royalty payments)

Kal Malhi
Name

CEO
Title

Mailing Address:

Bullrun Capital Inc.

Suite 915 -700 West Pender Street

Vancouver, VC, Canada

Email Address: kal@bullruncapital.ca

Phone: 604-805-4602

Fax:

Any false or misleading statements made, presented, or submitted to the **Government**, including any relevant omissions, under this **Agreement** and during the course of negotiation of this **Agreement** are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) and/or imprisonment).

APPENDIX A – PATENT(S) OR PATENT APPLICATION(S)

Patent(s) or Patent Application(s):

I. U.S. Patent Application Serial No 15/010,830, filed January 29, 2016, **HHS** Reference Number E-048-2010-0-US-05, titled "Agonist/antagonist compositions and methods of use";

II. U.S. Patent 9,277,748 (Application No. 13/634,447) filed March 11, 2011, issued March 8, 2016, titled "Agonist/antagonist compositions and methods of use", **HHS** Ref. No.: E-048-2010-0-US-04;

III. Canada Patent Application Serial No. 2,792,878, filed March 11, 2011, **HHS** Reference Number E-048-2010-0-CA-03 titled "Agonist/antagonist compositions and methods of use";

IV. PCT Patent Application Serial No. PCT/US2011/028132, filed March 11, 2011, now abandoned, **HHS** Reference Number E-048-2010-0-PCT-02 titled "Agonist/antagonist compositions and methods of use"; and

V. U.S. Provisional Patent Application No. 61/340,063, filed March 12, 2018, now abandoned, titled "Agonist/Antagonist Compositions and Methods of Use", **HHS** Ref. No.: E-048-2010-0-US-01.

APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY

I. **Licensed Fields of Use:**

(a) Generation of compositions containing a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist combined with a TRPV1 agonist for the temporary incapacitation of a subject.

II. **Licensed Territory:**

(a) Worldwide

APPENDIX C – ROYALTIES

Royalties:

I. The **Licensee** agrees to pay to the **IC** a noncreditable, nonrefundable license issue royalty in the amount of twenty thousand Dollars ($20,000) within sixty (60) days from the effective date of this **Agreement.**

II. The **Licensee** agrees to pay to the **IC** a nonrefundable minimum annual royalty in the amount of ten thousand Dollars ($10,000) as follows:

(a) The first minimum annual royalty is due within sixty (60) days of the effective date of this **Agreement** and may be prorated according to the fraction of the calendar year remaining between the effective date of this **Agreement** and the next subsequent January 1; and

(b) Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year.

III. The **Licensee** agrees to pay the **IC** earned royalties of:

(a) Five percent (5%) on **Net Sales** by or on behalf of the **Licensee** in the US and Canada; and

(b) Three percent (3%) on **Net Sales** by or on behalf of the **Licensee** in all jurisdictions other than Canada or the United States.

IV. The **Licensee** agrees to pay the **IC Benchmark** royalties within sixty (60) days of achieving each **Benchmark**:

(a) Eight thousand Dollars ($8,000) upon Completion of Pre-Clinical Acute Dermal/Ocular Toxicity Studies.

(b) Eight thousand Dollars ($8,000) upon Completion of a Phase I Clinical Trial.

(c) Ten thousand Dollars ($10,000) upon **First Commercial Sale.**

APPENDIX D – BENCHMARKS AND PERFORMANCE

The **Licensee** agrees to the following **Benchmarks** for its performance under this **Agreement** and, within thirty (30) days of achieving a **Benchmark**, shall notify the **IC** that the **Benchmark** has been achieved.

I. Select a first TRPV1 agonist/antagonist compounds for product development (Q1_ 2019)

II. Identify a manufacturer of the TRPV1 agonist/antagonist compound (Q2 2019)

III. Conduct pre-clinical acute dermal/ocular toxicity studies (Q3 2019)

IV. Conduct a Phase I clinical trial (Q2 2020)

V. **First commercial sale** of the first TRPV1 agonist/antagonist compound (Q1 2021)

APPENDIX E – COMMERCIAL DEVELOPMENT PLAN

Licensee intends to develop short acting pepper sprays that are effective at incapacitating a subject while also having the built-in ability to minimize the duration of the effects after exposure. The products would contain both a TRPV1 receptor agonist such as capsaicin, which would cause the typical pepper spray reaction, along with a TRPV1 receptor antagonist that would be used to counteract the effect of the agonist. **Licensee**'s development plans are as follows:

Since none of the agonist/antagonist combinations have been tested *in vivo*, the first step for **Licensee** will be to confirm which antagonists will work as needed. Following selection of specific combinations of agonists and antagonists to initially develop into commercial products, **Licensee** will explore the regulatory pathway needed to bring the product(s) to market. Although conventional pepper spray formulations do not require **FDA** approval, the addition of the antagonist may cause the product(s) to be viewed as a device containing a drug, such that there is a reasonable chance that the **FDA** will require oversight. Therefore, the company is already planning to manufacture their formulation(s) under cGMP standards while they investigate whether or not **FDA** approval or clearance will be required. The company will engage regulatory consultants who are experts in this area and will also apply directly to the **FDA** for guidance.

Once specific antagonists have been chosen for advancement, **Licensee** plans to identify a contract manufacturer. As noted above, given the chance that the product may require **FDA** review, **Licensee** intends to manufacture the antagonist material under cGMP regulations in order to produce clinical grade material. **Licensee** also realizes that the opinion of the **FDA** could change, and therefore, the company believes it is necessary to manufacture the anatomist under cGMP conditions, even if the initial decision from the **FDA** is that the formulation does not require clearance.

As part of the development process, **Licensee** intends to conduct pre-clinical acute dermal/ocular toxicity studies. These studies are acute one-time exposures that would likely be conducted on rabbits to measure lacrimation (crying/tears), followed by pathology tests on eye tissue after the animals are given a period of time to recover. Study costs will range depending on the number of different formulations and concentrations of agonist/antagonist being used in the study.

As part of finalizing the formulation(s), **Licensee** will conduct product stability studies, looking at how the product(s) manages at higher temperature (42°C) over a period of several months. **Licensee** expects these stability studies, which are used to determine shelf-life, to be ongoing, and will depend somewhat on what the **FDA** requires as well as on the number of concentrations and different liquid formulations to be tested.

Finally, **Licensee** plans to conduct a phase I clinical trial, although this could be run concomitantly with the stability studies. After a final or near-final formulation (or formulations) has been selected, **Licensee** will approach the **FDA** and/or Health Canada about clinical testing. The company anticipates that a single-dose related exposure study is what will be needed. Testing protocols will likely include eyes, skin and respiratory (inhalation) function.

Per the diagram below, **Licensee** expects that it will take about two years to develop the formulation(s) into a sales-ready product.


Milestone (Month)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Confirm Antagonist(s) for Development
FDA Route & Initial Manufacturing
Initial Manufacturing
Pre clinical GLP tox
Formulation & Stability
Solvent & Propellant
Canister Selection
Valve Selection
Actuator Selection
Valve Leakage Stability Study
Phase I Study
Product Labelling Design
Component Procurement & Delivery
Digital Promotional Materia
Development
Manufacturing Large Scale
Marketing and Advertisement
Sales

APPENDIX F – EXAMPLE ROYALTY REPORT

Required royalty report information includes:

- License reference number (L-XXX-200X/0)
- Reporting period
- Catalog number and units sold of each Licensed Product (domestic and foreign)
- Gross Sales per catalog number per country
- Total Gross Sales
- Itemized deductions from Gross Sales
- Total Net Sales
- Earned Royalty Rate and associated calculations
- Gross Earned Royalty
- Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made
- Net Earned Royalty due

Example

Catalog Number	Product Name	Country	Units Sold	Gross Sales (US$)
1	A	US	250	62,500
1	A	UK	32	16,500
1	A	France	25	15,625
2	B	US	0	0
3	C	US	57	57,125
4	D	US	12	1,500

Total Gross Sales	153,250
Less Deductions:	
Freight	3,000
Returns	7,000
Total Net Sales	143,250
Royalty Rate	8%
Royalty Due	11,460
Less Creditable Payments	10,000
Net Royalty Due	**1,460**

APPENDIX G – ROYALTY PAYMENT OPTIONS

New Payment Options Effective March 2018

The License Number MUST appear on payments, reports and correspondence.

Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S. Treasury web site located at: **https://www.pay.gov/public/form/start/28680443.**

Automated Clearing House (ACH) for payments through U.S. banks only

The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/startJ28680443. Please note that the "C "only" accepts ACH payments through this U.S. Treasury web site.

Electronic Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a **U.S. bank account** via FEDWIRE:

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the **NIH ROYALTY FUND**.

Fedwire Field Tag	Fedwire Field Name	Required Information
{1510}	Type/Subtype	**1000**
{2000}	Amount	*(enter payment amount)*
{3400}	Receiver ABA routing number*	**021030004**
{3400}	Receiver ABA short name	**TREAS NYC**
{3600}	Business Function Code	**CTR** *(or CTP)*
{4200}	Beneficiary Identifier (account number)	*(enter 12 digit gateway account #)* **875080031006**
{4200}	Beneficiary Name	*(enter agency name associated with the Beneficiary Identifier)* **DHHS / NIH (75080031)**
{5000}	Originator	*(enter the name of the originator of the payment)* **COMPANY NAME**
{6000}	Originator to Beneficiary Information – Line 1	*(enter information to identify the purpose of the payment)* **ROYALTY**
{6000}	Originator to Beneficiary Information – Line 2	*(enter information to identify the purpose of the payment)* **LICENSE NUMBER**
{6000}	Originator to Beneficiary Information – Line 3	*(enter information to identify the purpose of the payment)*

Fedwire Field Tag	Fedwire Field Name	Required Information
		INVOICE NUMBER
{6000}	Originator to Beneficiary Information – Line 4	*(enter information to identify the purpose of the payment)*
Notes: *The financial institution address for Treasury's routing number is 33 Liberty Street, New York, NY 10045.		

Agency Contacts: Office of Technology Transfer (OTT) (301) 496-7057 OTT-Royalties@mail.nih.gov

Drawn on a **foreign bank account** via FEDWIRE:

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD).

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable.

Fedwire Field Tag	Fedwire Field Name	Required Information
{1510}	Type/Subtype	**1000**
{2000}	Amount	*(enter payment amount)*
{3100}	Sender Bank ABA routing number	*(enter the US correspondent bank's ABA routing number)*
{3400}	Receiver ABA routing number*	**021030004**
{3400}	Receiver ABA short name	**TREAS NYC**
{3600}	Business Function Code	**CTR** (*or CTP*)
{4200}	Beneficiary Identifier (account number)**	*(enter 12 digit gateway account #)* **875080031006**
{4200}	Beneficiary Name	*(enter agency name associated with the Beneficiary Identifier)* **DHHS / NIH (75080031)**
{5000}	Originator	*(enter the name of the originator of the payment)* **COMPANY'S NAME**
{6000}	Originator to Beneficiary Information – Line 1	*(enter information to identify the purpose of the payment)* **ROYALTY**
{6000}	Originator to Beneficiary Information – Line 2	*(enter information to identify the purpose of the payment)* **LICENSE NUMBER**
{6000}	Originator to Beneficiary Information – Line 3	*(enter information to identify the purpose of the payment)* ***INVOICE NUMBER***
{6000}	Originator to Beneficiary Information – Line 4	*(enter information to identify the purpose of the payment)*
Notes: *The financial institution address for Treasury's routing number is 33 Liberty Street, New York, NY 10045. **Anything other than the 12 digit gateway account # will cause the Fedwire to be returned – **SWIFT CODE:**		

Fedwire Field Tag	Fedwire Field Name	Required Information
FRNYUS33		

Agency Contacts:

Office of Technology Transfer (OTT) (301) 496-7057 OTT-Royalties@mail.nih.gov

Checks

All checks should be made payable to "NIH Patent Licensing"

Checks drawn on a **U.S. bank account** and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health
P.O. Box 979071
St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent by **overnight or courier** should be sent to the following address:

US Bank
Government Lockbox SL-MO-C2GL
1005 Convention Plaza
St. Louis, MO 63101
Phone: 314-418-4087

Checks drawn on a **foreign bank account** should be sent directly to the following address:

National Institutes of Health
Office of Technology Transfer
License Compliance and Administration
Royalty Administration
6011 Executive Boulevard
Suite 325, MSC 7660
Rockville, Maryland 20852

SCHEDULE "B"

PAYMENT

In consideration of the assignment of the NCI License, the Assignee shall issue to the Assignor 10,000,000 Common Shares on the Effective Date as follows:

Name and Address of Registered Holder	**Number of Common Shares**
Sandip Rai 6650 Inverness Street Vancouver, BC V5X 4Z9 604-808-9751	2,000,000
Justin Sangha 4190 204 Street Langley BC V3A 1X8 604-761-8375	2,000,000
Milan Malhi 10589 Ladner Trunk Road Delta, BC V4G 1K2 604-616-2474	2,000,000
BullRun Capital Inc. 915-700 W Pender Street Vancouver BC V6C 1H2	4,000,000
TOTAL:	10,000,000